Novavax rises as biotech rally spreads after Merck-Moderna data
Novavax shares are trading higher Wednesday as a broad biotech rally follows Merck and Moderna Phase 3 INTerpath-001 melanoma results; no Novavax-specific catalyst was supplied.
Shares of Novavax Inc (NASDAQ: NVAX ) are trading higher Wednesday. The move comes as a major clinical victory in the oncology space generated widespread momentum across vaccine developers and the broader biotechnology sector. Novavax shares are climbing with conviction. Why are NVAX shares rallying?
Merck-Moderna Clinical Breakthrough Triggers Industry-Wide Momentum The catalyst lifting Novavax stems from landmark Phase 3 INTerpath-001 trial results released Wednesday by Merck & Co Inc and Moderna Inc. The partners announced that their individualized mRNA cancer vaccine, intismeran autogene, combined with Keytruda significantly improved recurrence-free survival in advanced melanoma patients. The historical readout, representing the first positive Phase 3 win for a custom cancer therapy, ignited a massive risk-on rally across the biopharmaceutical space.
The SPDR S&P Biotech ETF (NYSE: XBI ) spiked more than 4% early Wednesday, lifting pure-play vaccine makers alongside drug developers. Adjuvant Platform and Sector Re-Rating Support Novavax Rally While Novavax is traditionally recognized for its protein-based infectious disease vaccines, the late-stage validation of complex therapeutic vaccines highlights the growing industry importance of advanced delivery systems. Novavax continues to market its proprietary Matrix-M saponin-based adjuvant platform, which enhances immune responses and remains a key asset for potential partner licensing in oncology and respiratory combination pipelines.
34 at the time of publication on Wednesday, according to Pro data. Read Also: Treasury Just Doubled Its Bond Buybacks: What That Can and Can't Fix Image: Shutterstock